Ultomiris reduced the risk of relapse in a late-stage trial for the neuromyelitis optica spectrum disorder.

Data presented at the meeting will feature new insights from Alexion’s complement portfolio illustrating the critical role of C5 inhibition in treating AQP4 Ab+ NMOSD and significantly reducing the risk of relapses, including findings on the first and only long-acting C5 complement inhibitor, Ultomiris (ravulizumab-cwvz).

The trial evaluated Ultomiris (ravulizumab), a complement component 5 (C5) inhibitor, in 58 people with anti-aquaporin-4 (AQP4) auto antibody-positive (Ab+) NMOSD. NMOSD is an autoimmune condition that causes damage to the spinal cord and optic nerve and affects around 1-10 per 100,000 people worldwide. Those positive for anti-AQP4 auto-antibodies comprise around three quarters of the whole disease population and the condition often strikes around the age of 40 with women making up 90% of those affected. Patients can experience recurrent relapses that over time can lead to blindness, paralysis or even death,

The new CHAMPION-NMOSD data showed there were zero adjudicated on-trial relapses in Ultomiris-treated patients at a median treatment duration of 73 weeks, representing a relapse risk reduction of 98.6% (p<0.0001) compared with placebo.